The present invention provides use of EB1 as a biomarker for predicting the response of a brain neoplasm to a compound of formula (I) wherein R represents phenyl or pyridinyl; wherein phenyl is optionally substituted by one or two substituents independently selected from lower alkyl, lower alkoxy, amino, acetylamino, halogen and nitro; and wherein pyridinyl is optionally substituted by amino or halogen; R1 represents hydrogen or cyano-lower alkyl; or a pharmaceutically acceptable derivative thereof, and wherein the prefix lower denotes a radical having up to and including a maximum of 4 carbon atoms; in particular wherein a higher level of EB1 in the sample from the subject relative to a standard value or set of standard values predicts sensitivity of the brain neoplasm to the compound of formula I or pharmaceutically acceptable derivative thereof. The invention also provides methods of treatment and kits for use according to the invention.
Methods are disclosed for forming bone and/or cartilage in an avian subject. The methods include administering to the avian subject a therapeutically effective amount of a composition comprising avian mesenchymal stem cells and a hydrogel that supports the differentiation of the avian mesenchymal stem cells into cells of an osteogenic and/or condrogenic lineage. In some embodiments, methods are disclosed for repairing a bone defect and preventing infection, such as that associated bone fracture, in an avian subject. The methods include administering locally to the bone defect a composition comprising a therapeutically effective amount of avian mesenchymal stem cells and a hydrogel, such as a methacrylated gelatin hydrogel.
The present invention relates to a medium composition containing an Ecklonia cava extract for dediffentiating an induced pluripotent stem cell. Also, the present invention relates to a method for differentiating an induced plurlipotent stem cell produced by using the medium composition into a chondrocyte. When using the medium composition, according to the present invention, induced pluripotent stem cells using mesenchymal stem cells can be produced efficiently, and the pluripotent stem cells which have been produced can be useful as a cell treatment agent by being capable of being differentiated into chondrocytes.
Described herein are cells, cell culture methods, and cell culture media compositions useful for producing and maintaining iPSC-derived cell lines that are of higher purity and maintain cell type integrity better than current iPSC-derived cell lines. Also disclosed are methods of using the described cells and media, such as therapeutic methods of use for the described cells. The described cells include iPSC-derived mesodermal precursor cells (MPC), which itself may differentiate into at least four different cell types. When cultured under appropriate conditions, the mesodermal precursor cells can be used to produce hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), smooth muscle cells (SMC), or unlimited functional endothelial cells (UFEC). One characteristic that makes the described cells desirable is that they can be maintained in culture for a number of days, or passages, without changing phenotype through differentiation.
Kits and methods for treating cancer comprising administration of a gliadin peptide to a patient are disclosed herein. A kit according to the invention comprises a pharmaceutical composition comprising a gliadin peptide and instructions for administering the peptide to a patient. The kit may further comprise a pharmaceutical composition comprising at least one chemotherapeutic agent such as a receptor tyrosine kinase inhibitor and instructions for co¬ administering the compounds. A method of treating cancer according to the invention comprises administering a gliadin peptide to a patient and may further comprise co-administering at least one chemotherapeutic agent such as a receptor tyrosine kinase inhibitor. Co-administration of a gliadin peptide and receptor tyrosine kinase inhibitor to a patient with cancer is effective to decrease or prevent resistance of the cancer to the receptor tyrosine kinase inhibitor.
Provided herein are methods of differentiating tiophoblast stem cells via modulating miR-124, and the differentiated cells thereby. Also provided herein are methods for the treatment of diseases using the differentiated cells. The differentiated cells are pancreatic progenitor cells that express insulin, betatrophin and C-peptide.
The inventors disclose methods and systems that provide for the isolation and purification of neurons directly from heterogeneous cell cultures. The expression of various cell adhesion molecules was examined in pluripotent stem cells. Changes in the expression of one or more of these molecules correlates with the progression of cells from non-linage committed to neural cells. Using one or more antibodies for these molecules in combination with antibodies specific for CD200 will enable one to identify and isolate neurons from a population cells.
Embodiments of the invention are directed to compositions comprising a peptide sequence, or a nucleic acid encoding the same, wherein the peptide sequence includes a receptor-binding region of apolipoprotein E (apoE), or a sequence variant or fragment thereof, for directing delivery of a given protein or therapeutic across the blood brain barrier. Embodiments of the invention are also directed to methods of using the compositions for treating or preventing a neurological disorder, disease, or symptom in a subject in need thereof.
The present invention relates to a method for diagnosing a carcinoma or a residual disease associated thereto, or for the prognosis of a carcinoma, or for monitoring the effectiveness of an anti-tumour therapy directed against a carcinoma, or for monitoring the follow-up of an individual affected by a carcinoma, in particular colorectal carcinoma, carcinoma of the stomach, mammary carcinoma, pulmonary carcinoma or carcinoma of the prostate, carcinoma of the liver, carcinoma of the ovary, carcinoma of the kidney, carcinoma of the thyroid, carcinoma of the bladder or carcinoma of the pancreas. The method of the invention consists in placing adult stem cells in contact with a sample of a haemo-derivative of the individual to be analysed and in verifying the expression of at least an epithelial marker in the stem cells by means of immunofluorescence, immunohistochemistry, ELISA or RT-PCR.